Evidence map›Paper›PMID 41872648›Full record

SynthesisInternational urology and nephrology2026

Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis.

Guoqing Zhu, Xingyu Xiong, Zhufeng Peng, Weizhen Zhu, Weichao Huang, Jie Yang, Sheng Wang, Hang Xu, Lu Yang

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guoqing Zhu *Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xingyu Xiong *Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zhufeng Peng *Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Weizhen ZhuDepartment of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Weichao HuangDepartment of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jie YangDepartment of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Sheng WangDepartment of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Hang XuDepartment of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. hangxu@wchscu.cn.
Lu YangDepartment of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. wycleflue@scu.edu.cn.

Funding

National Key Research and Development Program 2024YFB3311703-1Natural Science Foundation of Sichuan, China 2025ZNSFSC1892the National Natural Science Foundation of China 82372831,82403963, 82170785the Postdoctor Research Fund of West China Hospital, Sichuan University 2025HXBH134
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA) positron emission tomography (PET) is emerging as an imaging modality with an established role for assessment of prostate cancer. This review aims to evaluate the impact of PSMA PET on the management and clinical outcomes in men with biochemical failure of prostate cancer.

methodsWe conducted a comprehensive literature search of the electronic databases from inception to August, 2025. The outcomes of interest included prostate-specific antigen (PSA) responses, biochemical recurrence-free survival (BRFS), biochemical progression-free survival (BPFS), and overall survival (OS). Meta-regression and subgroup analyses were conducted to explore the heterogeneity. Sensitivity analysis was performed to assess the robustness of the results.

resultsA total of 71 studies comprising 9948 patients were included in this systematic review and meta-analysis. The pooled proportion of patients experiencing a management change following PSMA PET was 53% (95% CI: 48-58%). A decrease in serum PSA level was observed in 75% (95% CI: 65-85%) of patients. For survival outcomes, the pooled estimates for 1-, 2-, and 3-year biochemical recurrence-free survival (BRFS) were 62% (95% CI: 52-71%), 66% (95% CI: 55-77%), and 62% (95% CI: 46-78%), respectively. The corresponding estimates for biochemical progression-free survival (BPFS) were 77% (95% CI: 65-88%), 84% (95% CI: 71-97%), and 79% (95% CI: 61-96%), respectively.

conclusionsThis meta-analysis suggests that PSMA PET-guided management is associated with favorable oncologic outcomes in men with biochemical recurrence, with over half of patients experiencing a change in management strategy and a substantial proportion demonstrating a biochemical response. Nevertheless, due to considerable heterogeneity across studies, these conclusions remain preliminary and require confirmation through more robust prospective evidence.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIPositron-Emission TomographyProstatic NeoplasmsHumansMaleProstate-Specific AntigenTreatment FailureTreatment OutcomeAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIProstate-Specific AntigenBiochemical failureManagement changeProstate cancerPSMA PETSurvival outcomes

Identifiers

PMID41872648

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.